Knight Therapeutics (OTCMKTS:KHTRF) Shares Up 0.6% – Time to Buy?

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shares traded up 0.6% during trading on Monday. The company traded as high as $7.22 and last traded at $7.22. Approximately 1,700 shares were traded during trading, a decline of 78% from the average session volume of 7,792 shares. The stock had previously closed at $7.18.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Knight Therapeutics in a report on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy”.

Knight Therapeutics Trading Up 0.6%

The company has a fifty day moving average price of $6.99 and a 200 day moving average price of $6.31.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative medicines. The company concentrates on therapies that address unmet medical needs, including specialty, orphan and hospital-based treatments.

Through licensing and commercialization agreements, Knight offers a portfolio of prescription products across therapeutic areas such as oncology, rare diseases, infectious diseases and neurology.